Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration

Katarzyna Michalska-Małecka,1,2 Adam Kabiesz,2 Malgorzata W Kimsa,3 Barbara Strzałka-Mrozik,3 Maria Formińska-Kapuścik,2,4 Malgorzata Nita,5 Urszula Mazurek31Clinical Department of Ophthalmology, Medical University of Silesia, Katowice, Poland; 2University Center for Ophthalmology and Oncology, Inde...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michalska-Małecka K, Kabiesz A, Kimsa MW, Strzałka-Mrozik B, Formińska-Kapuścik M, Nita M, Mazurek U
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	age-related macular degeneration ranibizumab contralateral eye central retinal thickness oligonucleotide microarray Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/2d040c05fe1d4d29ac10c7f79cd6139e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2d040c05fe1d4d29ac10c7f79cd6139e
record_format	dspace
spelling	oai:doaj.org-article:2d040c05fe1d4d29ac10c7f79cd6139e2021-12-02T06:58:51ZEffects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration1178-1998https://doaj.org/article/2d040c05fe1d4d29ac10c7f79cd6139e2016-03-01T00:00:00Zhttps://www.dovepress.com/effects-of-intravitreal-ranibizumab-on-the-untreated-eye-and-systemic--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Katarzyna Michalska-Małecka,1,2 Adam Kabiesz,2 Malgorzata W Kimsa,3 Barbara Strzałka-Mrozik,3 Maria Formińska-Kapuścik,2,4 Malgorzata Nita,5 Urszula Mazurek31Clinical Department of Ophthalmology, Medical University of Silesia, Katowice, Poland; 2University Center for Ophthalmology and Oncology, Independent Public Clinical Hospital, Medical University of Silesia, Katowice, Poland; 3Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Katowice, Poland; 4Clinical Department of Children Ophthalmology, Medical University of Silesia, Katowice, Poland; 5Domestic and Specialized Medicine Centre “Dilmed”, Katowice, PolandAbstract: The purpose of this study was to evaluate the systemic effects of intravitreal ranibizumab (Lucentis) treatment in patients with neovascular age-related macular degeneration (AMD). The impact of intravitreal ranibizumab injections on central retinal thickness (CRT) of treated and contralateral untreated eyes, and differences in gene expression patterns in the peripheral blood mononuclear cells were analyzed. The study included 29 patients aged 50 years old and over with diagnosed neovascular AMD. The treatment was defined as 0.5 mg of ranibizumab injected intravitreally in the form of one injection every month during the period of 3 months. CRT was measured by optical coherence tomography. The gene expression profile was assigned using oligonucleotide microarrays of Affymetrix HG-U133A. Studies have shown that there was a change of CRT between treated and untreated eyes, and there were differences in CRT at baseline and after 1, 2, and 3 months of ranibizumab treatment. Three months after intravitreal injection, mean CRT was reduced in the treated eyes from 331.97±123.62 to 254.31±58.75 µm, while mean CRT in the untreated fellow eyes reduced from 251.07±40.29 to 235.45±36.21 µm at the same time. Furthermore, the research has shown that among all transcripts, 3,097 expresses change after the ranibizumab treatment in relation to controls. Among these transcripts, 1,339 were up-regulated, whereas 1,758 were down-regulated. Our results show the potential systemic effects of anti-VEGF therapy for AMD. Moreover, our study indicated different gene expression in peripheral blood mononuclear cells before and after intravitreal ranibizumab treatment. Keywords: ranibizumab, contralateral eye, central retinal thickness, oligonucleotide microarrayCorrigendum for this paper has been published. Michalska-Małecka KKabiesz AKimsa MWStrzałka-Mrozik BFormińska-Kapuścik MNita MMazurek UDove Medical Pressarticleage-related macular degenerationranibizumabcontralateral eyecentral retinal thicknessoligonucleotide microarrayGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 11, Pp 357-365 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	age-related macular degeneration ranibizumab contralateral eye central retinal thickness oligonucleotide microarray Geriatrics RC952-954.6
spellingShingle	age-related macular degeneration ranibizumab contralateral eye central retinal thickness oligonucleotide microarray Geriatrics RC952-954.6 Michalska-Małecka K Kabiesz A Kimsa MW Strzałka-Mrozik B Formińska-Kapuścik M Nita M Mazurek U Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
description	Katarzyna Michalska-Małecka,1,2 Adam Kabiesz,2 Malgorzata W Kimsa,3 Barbara Strzałka-Mrozik,3 Maria Formińska-Kapuścik,2,4 Malgorzata Nita,5 Urszula Mazurek31Clinical Department of Ophthalmology, Medical University of Silesia, Katowice, Poland; 2University Center for Ophthalmology and Oncology, Independent Public Clinical Hospital, Medical University of Silesia, Katowice, Poland; 3Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Katowice, Poland; 4Clinical Department of Children Ophthalmology, Medical University of Silesia, Katowice, Poland; 5Domestic and Specialized Medicine Centre “Dilmed”, Katowice, PolandAbstract: The purpose of this study was to evaluate the systemic effects of intravitreal ranibizumab (Lucentis) treatment in patients with neovascular age-related macular degeneration (AMD). The impact of intravitreal ranibizumab injections on central retinal thickness (CRT) of treated and contralateral untreated eyes, and differences in gene expression patterns in the peripheral blood mononuclear cells were analyzed. The study included 29 patients aged 50 years old and over with diagnosed neovascular AMD. The treatment was defined as 0.5 mg of ranibizumab injected intravitreally in the form of one injection every month during the period of 3 months. CRT was measured by optical coherence tomography. The gene expression profile was assigned using oligonucleotide microarrays of Affymetrix HG-U133A. Studies have shown that there was a change of CRT between treated and untreated eyes, and there were differences in CRT at baseline and after 1, 2, and 3 months of ranibizumab treatment. Three months after intravitreal injection, mean CRT was reduced in the treated eyes from 331.97±123.62 to 254.31±58.75 µm, while mean CRT in the untreated fellow eyes reduced from 251.07±40.29 to 235.45±36.21 µm at the same time. Furthermore, the research has shown that among all transcripts, 3,097 expresses change after the ranibizumab treatment in relation to controls. Among these transcripts, 1,339 were up-regulated, whereas 1,758 were down-regulated. Our results show the potential systemic effects of anti-VEGF therapy for AMD. Moreover, our study indicated different gene expression in peripheral blood mononuclear cells before and after intravitreal ranibizumab treatment. Keywords: ranibizumab, contralateral eye, central retinal thickness, oligonucleotide microarrayCorrigendum for this paper has been published.
format	article
author	Michalska-Małecka K Kabiesz A Kimsa MW Strzałka-Mrozik B Formińska-Kapuścik M Nita M Mazurek U
author_facet	Michalska-Małecka K Kabiesz A Kimsa MW Strzałka-Mrozik B Formińska-Kapuścik M Nita M Mazurek U
author_sort	Michalska-Małecka K
title	Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
title_short	Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
title_full	Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
title_fullStr	Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
title_full_unstemmed	Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
title_sort	effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/2d040c05fe1d4d29ac10c7f79cd6139e
work_keys_str_mv	AT michalskamałeckak effectsofintravitrealranibizumabontheuntreatedeyeandsystemicgeneexpressionprofileinagerelatedmaculardegeneration AT kabiesza effectsofintravitrealranibizumabontheuntreatedeyeandsystemicgeneexpressionprofileinagerelatedmaculardegeneration AT kimsamw effectsofintravitrealranibizumabontheuntreatedeyeandsystemicgeneexpressionprofileinagerelatedmaculardegeneration AT strzałkamrozikb effectsofintravitrealranibizumabontheuntreatedeyeandsystemicgeneexpressionprofileinagerelatedmaculardegeneration AT forminskakapuscikm effectsofintravitrealranibizumabontheuntreatedeyeandsystemicgeneexpressionprofileinagerelatedmaculardegeneration AT nitam effectsofintravitrealranibizumabontheuntreatedeyeandsystemicgeneexpressionprofileinagerelatedmaculardegeneration AT mazureku effectsofintravitrealranibizumabontheuntreatedeyeandsystemicgeneexpressionprofileinagerelatedmaculardegeneration
_version_	1718399622310789120

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration

Ejemplares similares